PTC Therapeutics shares are down about 3% in Thursday trading, with sentiment still weighed by the company’s February 12, 2026 decision to withdraw its New Drug Application resubmission for Translarna (ataluren) in nonsense mutation Duchenne muscular dystrophy after FDA feedback indicated the submission was unlikely to meet the agency’s threshold for approval. The lack of a new, clearly identifiable company-specific headline today suggests the decline is largely overhang-driven and positioning-related, amplified by typical biotech volatility.

The Translarna U.S. withdrawal removed a potential U.S. commercial upside scenario for ataluren and refocused investor attention on PTC’s other value drivers, including the Sephience (sepiapterin) launch and the broader rare-disease/CNS pipeline. When a high-profile regulatory pathway closes, biotechs can see continued multiple compression as the market rebalances probability-weighted revenue expectations and shifts capital toward nearer-term, de-risked assets.

Investors will be watching for updated commercial traction for Sephience, progress on late-stage pipeline plans, and any new guidance on regulatory strategy following the Translarna setback. Any incremental disclosures around timing, trial designs, or regulatory feedback—especially for programs viewed as potential accelerated-approval candidates—could quickly become the next driver of PTCT’s day-to-day moves.